Luxdegalutamide

Small molecule

Also known as ARV-766, JSB462

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Metastatic Castration-Resistant Prostate Cancer
NCT07047118 · Novartis Pharmaceuticals
2025-07-03 – 2028-05-14 · Prostatic Cancer, Castration-Resistant
What this study did
Other / comorbidity
NCT06991556 · Novartis Pharmaceuticals
2025-07-07 – 2035-10-18 · Metastatic Hormone-sensitive Prostate Cancer
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT07206056 · Novartis Pharmaceuticals
2025-10-15 – 2030-12-01 · Progressive Metastatic Castrate Resistant Prostate Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT07174063 · Novartis Pharmaceuticals
2025-11-26 – 2027-01-29 · Metastatic Prostate Cancer (mCRPC)
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Luxdegalutamide: this drugPhase 2Small moleculeAndrogen receptor, Androgen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
Elfetabart DrozuntecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
FluzoparibPhase 3Small moleculePARP (poly ADP-ribose polymerase), specifically PARP-1not yet gradedNo reviewed efficacy summary in this indication
HRS-4357Phase 3UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
MevrometostatPhase 3Small moleculeEZH2not yet gradedNo reviewed efficacy summary in this indication
OpevesostatPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
PasritamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Rezvilutamide
Phase 3(overall)
Small moleculeAndrogen receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Zadavotide GuraxetanPhase 3Radioconjugate (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
HRS-5041
Phase 2(overall)
Small moleculeAndrogen receptor (degrader)
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-969Phase 1UndisclosedPSMA / STEAP1not yet gradedNo reviewed efficacy summary in this indication
AKY-2519Phase 1RadiopharmaceuticalB7-H3-targeted radioligand therapynot yet gradedNo reviewed efficacy summary in this indication
BPX-601Phase 1Cell therapyPSCAnot yet gradedNo reviewed efficacy summary in this indication
GSK5471713
—(overall)
UndisclosedAndrogen receptor (degrader)
not yet graded(overall)
No reviewed efficacy summary in this indication
RG6852
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Luxdegalutamide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Metastatic Hormone-sensitive Prostate CancerActive not recruiting
Est. primary completion 2026-12-03 · NCT06991556 · CT.gov ↗
What to watch
2027 (3)
January 2027 (1)
Phase 1Metastatic Prostate Cancer (mCRPC)Active not recruiting
Est. primary completion 2027-01-29 · NCT07174063 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Prostate Cancer MetastaticActive not recruiting
Est. primary completion 2027-05-25 · NCT05067140 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-07-16 · NCT07047118 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
Phase 1/2Progressive Metastatic Castrate Resistant Prostate CancerRecruiting
Est. primary completion 2029-11-09 · NCT07206056 · CT.gov ↗
What to watch

See the full readout calendar ↗